
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
National report ? While topical calcineurin inhibitors for treating atopic dermatitis (AD) continue to grab headlines, sources tell Dermatology Times that research into additional treatments for pediatric skin problems is progressing.






